Naltrexone And Bupropion
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
Orexigen Therapeutics, Inc · Phase 2/3 · Completed · Enrollment 3
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.